This article forms part of a paid educational collaboration with Melna Oncology Centre.
Public awareness around lung cancer has long been dominated by one message: smoking dramatically increases risk. While this remains true, it has also created a damaging misconception — that only smokers develop lung cancer.
In reality, a significant number of lung cancer cases occur in people who have never smoked, a trend increasingly recognised globally and within South Africa.
Understanding this overlooked risk is essential. Non-smokers often delay seeking medical help because they assume they are “not the type” to develop lung cancer, which can result in later diagnoses and fewer treatment options.
According to Dr Thandeka Buthelezi-Zulu, delayed presentation among non-smokers frequently leads to more advanced-stage diagnoses. In clinical practice, patients who do not recognise their symptoms as potentially serious often present later, significantly narrowing available treatment options.
Early-stage disease may allow for curative approaches, whereas later-stage disease often requires systemic therapy with more limited scope.
How Common Is Lung Cancer in Non-Smokers?
International studies estimate that approximately 10–20% of lung cancer diagnoses occur in people who have never smoked. While South Africa does not yet have comprehensive national data specifically for this subgroup, clinical patterns observed locally reflect global trends, indicating that non-smoking lung cancer is more common than many realise.
Medically, a “never-smoker” refers to someone who has smoked fewer than 100 cigarettes in their lifetime. In these patients, underlying biological or environmental factors often drive lung cancer rather than lifestyle habits.
What Causes Lung Cancer in Non-Smokers?
Lung cancer in non-smokers has distinct characteristics compared to smoking-related disease. Recognised contributing factors include genetic mutations, environmental exposures such as air pollution or biomass smoke, second-hand smoke, occupational hazards like diesel fumes or asbestos, prior lung inflammation, and family history.
These factors show that biology and the environment drive lung cancer in non-smokers — not personal behaviour.
Dr Buthelezi-Zulu notes that common barriers to early presentation include the misconception that lung cancer only affects smokers, dismissal of vague symptoms such as cough or fatigue, and fear or denial around a possible diagnosis. Practical challenges such as financial constraints, transport difficulties, and time away from work may further delay evaluation.
She advises patients to seek medical assessment for persistent respiratory symptoms regardless of smoking history, as earlier investigation can meaningfully improve outcomes.
Symptoms Non-Smokers Should Never Ignore
One of the greatest risks for non-smokers is underestimating early symptoms. Warning signs may include a persistent cough lasting more than three weeks, shortness of breath, chest discomfort, recurrent chest infections, coughing up blood, fatigue, or unexplained weight loss.
These symptoms are often dismissed as allergies, flu, or minor infections. This delay is one of the reasons non-smoking lung cancer is sometimes diagnosed at a later stage.
Why Early Diagnosis Matters
Early evaluation plays a critical role in lung cancer care, as it broadens available treatment options, improves the likelihood of responding to targeted therapies, and may allow for less invasive treatment pathways. Patients diagnosed earlier often experience better quality of life and more favourable long-term outcomes.
Diagnosis typically begins with a clinical examination, followed by imaging such as a chest X-ray or CT scan, and a biopsy if required. These steps form the foundation of safe, accurate cancer detection.
At Melna Oncology Centre, diagnostic pathways are coordinated locally, and treatment planning and follow-up care are managed to ensure continuity for patients, even when certain imaging must be completed at external facilities.
Dr Buthelezi-Zulu explains that early diagnosis allows treatment planning to shift from predominantly palliative approaches to potentially curative strategies. In non-smokers, early identification also enables timely molecular testing, which is critical for selecting targeted therapies and improving treatment tolerance.
The Role of Genomic Profiling
Genomic testing has become a central pillar in evaluating lung cancer in people who have never smoked. Unlike smoking-related cancers, which often involve widespread DNA damage, lung cancers in non-smokers tend to arise from a smaller number of specific, identifiable genetic mutations.
Through analysis of tumour tissue or specialised blood tests, genomic profiling helps oncologists identify driver mutations, assess whether targeted therapies are appropriate, and better understand disease behaviour. This allows treatment to be aligned with the tumour’s molecular characteristics rather than relying on broader, non-specific approaches.
Dr Buthelezi-Zulu highlights that genomic profiling has significantly improved treatment precision for non-smokers in the region, allowing patients to receive therapies better suited to their tumour biology while reducing unnecessary toxicity.
Treatment Options for Non-Smoking Lung Cancer
Treatment for lung cancer in non-smokers is increasingly individualised, as the cancer’s molecular profile, stage, and the patient’s overall health shape decisions. Once diagnostic imaging and genomic testing are complete, oncologists assess the evidence-based options most appropriate for each patient.
Oncologists may prioritise targeted therapies when tests identify actionable mutations such as EGFR or ALK. They may consider immunotherapy when tumour markers suggest potential benefit. Chemotherapy remains a widely used and effective option depending on cancer type and stage, while radiotherapy plays an important role in local tumour control or symptom relief.
Melna Oncology Centre provides radiotherapy planning and ongoing oncology oversight as part of its comprehensive cancer services. While radiotherapy treatment itself is delivered at partnered centres outside Newcastle due to the absence of a local radiotherapy unit, patients remain under the direct care of Dr Thandeka Buthelezi-Zulu throughout the process.
Treatment planning, coordination, and follow-up continue locally, ensuring continuity of care.
Furthermore, Dr Buthelezi-Zulu emphasises that the tumour’s molecular profile directly informs treatment selection. When tests identify actionable mutations, oncologists prioritise targeted therapies due to their effectiveness and tolerability. Where no actionable targets are present, tumour markers, disease stage, and patient factors guide treatment decisions to ensure an evidence-based, personalised approach.
Barriers to Early Detection Locally
Non-smokers in Northern KwaZulu-Natal often face challenges in recognising and responding to potential lung cancer symptoms. Limited awareness of personal risk, combined with misconceptions about who develops lung cancer, frequently delays medical consultation.
Access to advanced imaging may require travel, and economic or logistical constraints can further complicate early assessment. Melna Oncology Centre assists patients by coordinating treatment planning, providing local systemic therapy and follow-up care, and guiding patients through appropriate diagnostic pathways.
What to Do if You’re Concerned
Lung cancer in non-smokers is real, often misunderstood, and increasingly recognised in modern oncology. Awareness remains the first line of defence. Earlier evaluation, improved diagnostic tools, and personalised treatment approaches have significantly expanded effective care options for non-smokers.
Through coordinated planning, supportive care, and evidence-based treatment pathways, Melna Oncology Centre continues to assist patients in Northern KwaZulu-Natal who face this diagnosis — offering clarity, continuity, and medically grounded care close to home.
According to Dr Buthelezi-Zulu, recognising symptoms early and seeking timely assessment can meaningfully change outcomes and allow patients access to a broader range of treatment options.
For more information or to enquire about consultations, please visit www.melnaoncology.co.za or contact 034 317 3460.
What are your thoughts on this? Be sure to let us know in the comment section below.
Do not forget to read, Precision Oncology In Northern KZN: Personalised, World-Class Cancer Care, if you missed it.
Frequently Asked Questions:
Yes. A meaningful percentage of lung cancer cases occur in people who have never smoked. In these patients, genetic mutations, environmental exposure, family history, or previous lung inflammation often link to cancer rather than tobacco use.
Do not ignore a persistent cough lasting more than three weeks, shortness of breath, chest discomfort, unexplained fatigue, recurrent chest infections, coughing up blood, or unexplained weight loss — even in non-smokers.
Many non-smokers assume they are not at risk and dismiss early symptoms as minor illnesses such as allergies or flu. This delay in seeking medical advice can result in diagnosis at a more advanced stage of the disease.
Possible causes include genetic mutations, exposure to air pollution or biomass smoke, second-hand smoke, occupational hazards such as diesel fumes or asbestos, prior lung infections, and family history.
Genomic testing identifies specific mutations driving the cancer. This allows oncologists to select targeted therapies that suit the tumour’s biology rather than relying only on traditional chemotherapy.
Yes. Because non-smokers often have identifiable genetic mutations, treatment can often be more personalised using targeted therapies and molecular profiling to guide decisions.
Seek medical evaluation as soon as possible. Early imaging and assessment can significantly improve treatment options and outcomes when doctors detect a problem early.
Melna Oncology Centre in Newcastle provides coordinated diagnostic planning, treatment oversight, and follow-up care for patients in the region, ensuring continuity of care close to home.
One Response
It is nice to see a newcastle doctor taking the time to discuss these serious problems. When my husband was diagnosed in durban we were just told the basics and not to worry, which made us worry even more. many doctors have forgot that educating patients is a big part of their job. well done and keep it up